96980-65-3

Basic information

• Product Name: N-CHLOROACETYL-2,4-DIFLUOROANILINE
• Synonyms: TIMTEC-BB SBB002365;N-(2,4-DIFLUOROPHENYL)-2-CHLOROETHANAMIDE;N1-(2,4-DIFLUOROPHENYL)-2-CHLOROACETAMIDE;N-CHLOROACETYL-2,4-DIFLUOROANILINE;AKOS BBS-00003885;2-CHLORO-N-(2,4-DIFLUOROPHENYL)ACETAMIDE;2-CHLORO-2',4'-DIFLUOROACETANILIDE;N-Chloroacetyl-2,4-difluoroaniline 97%
• CAS NO: 96980-65-3
• Molecular Formula: C₈H₆ClF₂NO
• Molecular Weight: 205.59
• Mol File: 96980-65-3.mol
• Article Data: 19

Chemical Properties

• Melting Point: 79 °C
• Boiling Point: 313.1 °C at 760mmHg
• Flash Point: 143.2 °C
• Appearance: /
• Density: 1.444 g/cm³
• Vapor Pressure: 0.000506mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: N-CHLOROACETYL-2,4-DIFLUOROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-CHLOROACETYL-2,4-DIFLUOROANILINE(96980-65-3)
• EPA Substance Registry System: N-CHLOROACETYL-2,4-DIFLUOROANILINE(96980-65-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 96980-65-3(Hazardous Substances Data)

Usage

General Description

N-Chloroacetyl-2,4-difluoroaniline is a chemical compound with the molecular formula C8H6ClF2N. It is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. N-CHLOROACETYL-2,4-DIFLUOROANILINE is a chlorinated derivative of 2,4-difluoroaniline, making it useful in the production of various fluorinated organic compounds. It is important to handle this chemical with caution, as it is a potential irritant to the skin, eyes, and respiratory system. Additionally, it should be stored and used in a well-ventilated area with proper personal protective equipment to minimize exposure.

InChI:InChI=1/C8H6ClF2NO/c9-4-8(13)12-7-2-1-5(10)3-6(7)11/h1-3H,4H2,(H,12,13)

Upstream product

• 367-25-9 2,4-difluorophenylamine 
• 79-04-9 chloroacetyl chloride 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 183988-42-3 N-(2,4-Difluoro-phenyl)-2-(2-oxo-2-phenyl-ethylsulfanyl)-acetamide 
• 477320-15-3 N-(2,4-difluorophenyl)-2-[4-(2-pyridinyl)-1-piperazinyl]acetamide 
• 249933-10-6 N-(2,4-Difluorophenyl)-2-[5-methoxy-1-(toluene-4-sulphonyl)-1H-indazol-3-yloxy]acetamide 
• 1093981-68-0 C₈H₆F₂N₄O 

Relevant articles and documents

Synthesis and Biological Evaluation of Dithiobisacetamides as Novel Urease Inhibitors

Thirty-eight disulfides containing N-arylacetamide were designed and synthesized in an effort to develop novel urease inhibitors. Biological evaluation revealed that some of the synthetic compounds exhibited strong inhibitory potency against both cell-free urease and urease in intact cell with low cytotoxicity to mammalian cells even at concentration up to 250 μM. Of note, 2,2′-dithiobis(N-(2-fluorophenyl)acetamide) (d7), 2,2′-dithiobis(N-(3,5-difluorophenyl)acetamide) (d24), and 2,2′-dithiobis(N-(3-fluorophenyl)acetamide) (d8) were here identified as the most active inhibitors with IC50 of 0.074, 0.44, and 0.81 μM, showing 32- to 355-fold higher potency than the positive control acetohydroxamic acid. These disulfides were confirmed to bind urease without covalent modification of the cysteine residue and to inhibit urease reversibly with a mixed inhibition mechanism. They also showed very good anti-Helicobacter pylori activities with d8 showing a comparable potency to the clinical used drug amoxicillin. The impressive in vitro biological profile indicated their immense potential as therapeutic agents to tackle H. pylori caused infections.

Novel (thio)barbituric-phenoxy-N-phenylacetamide derivatives as potent urease inhibitors: synthesis, in vitro urease inhibition, and in silico evaluations

A novel series of (thio)barbituric-phenoxy-N-phenylacetamide derivatives 7a-l was synthesized and evaluated against Helicobacter pylori urease. The latter assay revealed that all the synthesized compounds 7a-l (IC50 = 0.69 ± 0.33–2.47 ± 0.23?μM

Naproxen based 1,3,4-oxadiazole derivatives as EGFR inhibitors: Design, synthesis, anticancer, and computational studies

A library of novel naproxen based 1,3,4-oxadiazole derivatives (8–16 and 19–26) has been synthesized and screened for cytotoxicity as EGFR inhibitors. Among the synthesized hy-brids, compound2-(4-((5-((S)-1-(2-methoxynaphthalen-6-yl)ethyl)-1,3,4-oxadiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)phenol(15) was the most potent compound against MCF-7 and HepG2cancer cells with IC50 of 2.13 and 1.63 μg/mL, respectively, and was equipotent to doxorubicin (IC50 1.62 μg/mL) towards HepG2. Furthermore, compound 15 inhibited EGFR kinase with IC50 0.41 μM compared to standard drug Erlotinib (IC50 0.30 μM). The active compound induces a high percentage of necrosis towards MCF-7, HePG2 and HCT 116 cells. The docking studies, DFT and MEP also supported the biological data. These results demonstrated that these synthesized naproxen hybrids have EGFR inhibition effects and can be used as leads for cancer therapy.